Drugs / Sodium Heparin UQ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03113084 | Aug 2022 → Apr 2023 | hyperheparinemia | Uniao Quimica | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Heparin UQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03113084 ↗ |
| Route | Subcutaneous | “Sodium heparin UQ subcutaneous drug administration” NCT03113084 ↗ |